Allovate and Restore Health Sign Exclusive Agreement to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Allovate and Restore Health Sign Exclusive Agreement to Bring Allerdent, the First Anti-Allergy Toothpaste System, to Allergy Sufferers

New York, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Allovate, LLC, a specialty biopharmaceutical company, today announced that the company has signed an exclusive provider agreement with Restore Health to bring the new Allerdent OMIT System™, a personalized toothpaste system for the delivery of allergy immunotherapy, to patients nationwide.  

Allerdent™ is the first oral mucosal immunotherapy (OMIT) toothpaste system designed to help moderate-to-severe allergy sufferers address the underlying cause of allergic response through their normal daily tooth brushing routine. It is customized and prescribed by a physician to address a wide range of allergies. With consistent use, allergy immunotherapy has been shown to significantly reduce or eliminate the body's allergic responses to pollen, animal dander, dust, insects and other allergens. Additionally, where allergy immunotherapy has been used on a sustained basis for between three and five years, its benefits have been shown to continue even after stopping treatment.

"Our agreement with Restore Health will make the Allerdent OMIT System™ available in all of the 49 states Restore Health currently serves. We are excited to partner with Restore Health, an innovator in personalized medicine, to roll-out the Allerdent OMIT System™ to providers throughout the United States," said Michael Nelson, J.D., co-founder and CFO of Allovate.

"Allovate is changing the way patients and physicians treat moderate to severe allergies. No other company is able to offer this new, convenient and personalized treatment to the more than 50 million moderate-to-severe allergy sufferers in the United States, without disrupting their normal lifestyle," said Erick Berglund, PhD., co-founder and CEO of Allovate.

"Through Restore Health, we are able to provide a customized, user-friendly allergy immunotherapy toothpaste system. Our OMIT toothpaste is designed to enable allergy immunotherapy without injections, frequent trips to the physician, or inconvenient treatment regimens. These are the typical issues both patients and physicians have with immunotherapy shots and drops that, unfortunately, have limited the use of this life-altering treatment."

Allergy immunotherapy has long been used to help desensitize the body to allergens such as pollen. By exposing the body's immune system over time to purified proteins like those found in allergens, the body learns to recognize them and stops or limits allergic response to them. "Most people treat allergies to pollen, dust, and animals with over-the-counter medications, which work temporarily but fail to address the underlying causes of the allergic response. Others just decide to live with their symptoms. A few seek allergy shots, which are helpful in reducing allergic symptoms by helping the immune systems adjust to allergens over time," said Dr. Berglund. "Our aim is to make it easier for people suffering allergy symptoms to address the underlying cause of the allergic response."

Shara Rudner, RPh., FIACP, FACA, Director, Clinical Trials Group for Restore Health, partnered with the research team at Allovate that developed the new toothpaste delivery system. Research results were published in the July/August 2014 issue: International Journal of Pharmaceutical Compounding . "The research shows that using a toothpaste delivery system to treat patients with seasonal allergies is very promising," said Rudner.

Restore Health is the first trusted national brand wholly dedicated to bringing personalized medicines to patients throughout the United States. The company delivers personalized and specialty medicines to patients, on their physicians' prescriptions. Restore provides cutting-edge diagnostics, including genetic testing, and custom pharmacies with service networks stretching from coast to coast. This year, for the second year running, Restore continued to climb the Inc. 500 list of the nation's fastest growing private companies, now ranking 36 th overall and first in Wisconsin.  

"Our agreement to provide the Allerdent OMIT System™ will ensure our customers have immediate access to this new treatment option," said Murray I. Firestone, Ph.D., President of Restore Health. "Restore is always working to accelerate the availability of novel therapies, from 'bench to bedside'.

Physicians interested in prescribing should call Restore Health at 800-322-1302 .

About Allovate, LLC

Allovate, LLC is a specialty biopharmaceutical company in New York City that is developing improved approaches to allergen-specific immunotherapy for the treatment of allergic diseases. Allergic diseases affect more than 25% of the global industrial population, at an annual cost in excess of $33 billion in the U.S. alone. There is an enormous and growing unmet need for treatment options that modify the underlying disease rather than treating the symptoms alone. Allovate's mission is to expand the use of immunotherapy among the millions of allergy sufferers by developing products that are safer, more effective, and easier to administer. Allovate's premiere product is Allerdent™, specially formulated toothpaste that is easily and stably combined with immunotherapy allergens. Thus, a patient's daily immunotherapy administration can be seamlessly integrated with the ritual of daily tooth-brushing, a habitual lifelong healthcare behavior for most people. Allerdent™ has been developed to support long-term patient adherence to immunotherapy, which may result in more successful and long-lasting treatments. For more information, please visit www.allovate.com .
 

About Restore Health

Restore Health is the first trusted national brand wholly dedicated to bringing personalized and specialty medicines to healthcare providers and their patients throughout the United States. Its unique full-service solution offers physicians integrated support of custom pharmacy, diagnostic laboratory, and clinical liaison personnel. RestoreDirect is the company's proprietary I.T. platform, a cloud-based, HIPAA-compliant, enterprise resource planning (ERP) software suite. It was originally conceived nearly a decade ago and designed to meet the unique, business-critical requirements of a specialty compounding pharmacy operating in the personalized medicine space. Mirroring the growth of Restore Health and its creation of a trusted national brand, the RestoreDirect suite of integrated business applications has expanded to support Restore's remote sites and external trading partners through the full spectrum of secure transactions. Since 1982, Restore Health has established a reputation among physicians for providing personalized medications and guidance that truly make a difference in their patients' lives. For more information about Restore Health, please visit www.restorehc.com . 

###

Virginia Amann for Allovate 608.207.0082

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading